Company intelligence / Profile preview

Sanaria Inc.

Rockville, Maryland, United Statessanaria.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Sanaria's PfSPZ Vaccine has shown high efficacy in clinical trials, with protection rates ranging from 41-86% over 18 months without booster doses. The PfSPZ-CVac vaccine demonstrated 100% protection against controlled human malaria infection at three months post-immunization. The newest PfSPZ-LARC2 Vaccine is designed to provide high-level protection with just a single dose and is preparing for first-in-human trials.

Therapeutic areas: Infectious Diseases
Modalities: Whole-parasite sporozoite vaccinesHuman monoclonal antibodies
Industry: Biotech

Drug pipeline

14 assets

PfSPZ Vaccine

13 more assets in the full pipeline.

Request access →

Partnerships

NIHSeattle Children's Research Institute's Center for Global Infectious Disease Research (CGIDR)

Beyond the preview

Go deeper on Sanaria Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanaria Inc..

Explore the full profile